Objective To investigate the clinical efficacy of preoperative three-dimensional radiotherapy (3DRT) with or without concurrent chemotherapy for esophageal carcinoma. Methods We retrospectively analyzed 103 esophageal carcinoma patients who received preoperative 3DRT with or without concurrent chemotherapy from 2004 to 2014 in Cancer Hospital CAMS. The median radiation dose was 40 Gy, and the TP or PF regimen was adopted for concurrent chemotherapy if needed. The overall survival (OS) and disease-free survival (DFS) were calculated by the Kaplan-Meier method,and the survival difference and univariate prognostic analyses were performed by the log-rank test. The Cox proportional hazards model was used for multivariate prognostic analysis. Results The number of patients followed at 3-years was 54.The 3-year OS and DFS rates were 61.1% and 54.9%, respectively, for all patients. There were no significant differences between the 3DRT and concurrent chemoradiotherapy (CCRT) groups as to OS (P=0.876) and DFS (P=0.521). The rates of complete, partial, and minimal pathologic responses of the primary tumor were 48.0%, 40.2%, and 11.8%, respectively. There were significant differences in OS and DFS between the complete, partial, and minimal pathologic response groups (P=0.037 and 0.003). No significant difference in pathologic response rate was found between the 3DRT and CCRT groups (P=0.953). The lymph node metastasis rate was 26.5%, and this rate for the complete, partial, and minimal pathologic response groups was 14%, 30%, and 67%, respectively, with a significant difference between the three groups (P=0.001). The OS and DFS were significantly higher in patients without lymph node metastasis than in those with lymph node metastasis (P=0.034 and 0.020). The surgery-related mortality was 7.8% in all patients. Compared with the 3DRT group, the CCRT group had significantly higher incidence rates of leukopenia (P=0.002), neutropenia (P=0.023), radiation esophagitis (P=0.008), and radiation esophagitis (P=0.023). Pathologic response of the primary tumor and weight loss before treatment were independent prognostic factors for OS and DFS (P=0.030,0.024 and P=0.003,0.042). Conclusions Preoperative 3DRT alone or with concurrent chemotherapy can result in a relatively high complete pathologic response rate, hence increasing the survival rate. Further randomized clinical trials are needed to confirm whether preoperative CCRT is better than 3DRT in improving survival without increasing the incidence of adverse reactions.
. Clinical efficacy of preoperative three-dimensional radiotherapy with or without concurrent chemotherapy for esophageal carcinoma[J]. Chinese Journal of Radiation Oncology, 2016, 25(3): 220-225.
[1] Ajani JA,D′Amico TA,Almhanna K,et al. Esophageal and esophagogastric junction cancers,version 1.2015[J].J Natl Compr Cancer Netw,2015,13(2):194-227. [2] van Hagen P,Hulshof MCCM,van Lanschot JJB,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J].N Engl J Med,2012,366(22):2074-2084.DOI:10.1056/NEJMoa1112088. [3] Sjoquist KM,Burmeister BH,Smithers BM,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis[J].Lancet Oncol,2011,12(7):681-692.DOI:10.1016/S1470-2045(11)70142-5. [4] Kranzfelder M,Schuster T,Geinitz H,et al. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer[J].Br J Surg,2011,98(6):768-783.DOI:10.1002/bjs.7455. [5] 汪楣,谷铣之,黄国俊,等.食管癌术前放射治疗的前瞻性临床研究[J].中华放射肿瘤学杂志,2001,10(3):168-171.DOI:10.3760/j.issn:1004-4221.2001.03.007. Wang M,Gu XZ,Huang GJ,et al. Randomized trial on combined pre-operative irradiation and surgery in the treatment of esophageal carcinoma-report on 418 patients[J].Chin J Radiat Oncol,2001,10(3):168-171.DOI:10.3760/j.issn:1004-4221.2001.03.007. [6] Launois B,Delarue D,Campion JP,et al. Preoperative radiotherapy for carcinoma of the esophagus[J].Surg Gynecol Obstet,1981,153(5):690-692. [7] Gignoux M,Roussel A,Paillot B,et al. The value of preoperative radiotherapy in esophageal cancer:results of a study by the EORTC[J].Recen. Results Cancer Res,1988,110:1-13.DOI:10.1007/978-3-642-83293-2_1. [8] Wang M,Gu XZ,Yin WB,et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma:report on 206 patients[J].Int J Radiat Oncol Biol Phys,1989,16(2):325-327.DOI:10.1016/0360-3016(89)90323-4. [9] Arnott SJ,Duncan W,Kerr GR,et al. Low dose preoperative radiotherapy for carcinoma of the oesophagus:results of a randomized clinical trial[J].Radiother Oncol,1992,24(2):108-113.DOI:10.1016/0167-8140(92)90287-5. [10] Nygaard K,Hagen S,Hansen HS,et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma:a randomized,multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer[J].World J Surg,1992,16(6):1104-1109.DOI:10.1007/BF02067069. [11] Arnott SJ,Duncan W,Gignoux M,et al. Preoperative radiotherapy for esophageal carcinoma[J].Cochrane Database Syst Rev,2005,(4):CD001799.DOI:10.1002/14651858.CD001799.pub2. [12] 欧广飞,汪楣,王绿化,等.食管癌术前放疗后病理反应与预后的关系[J].中华肿瘤杂志,2003,25(3):278-281.DOI:10.3760/j.issn:0253-3766.2003.03.021. Ou GF,Wang M,Wang LH,et al. Relation between pathologic tumor response to preoperative radiotherapy and the prognosis in patients with esophageal carcinoma[J].Chin J Oncol,2003,25(3):278-281.DOI:10.3760/j.issn:0253-3766.2003.03.021. [13] Meredith KL,Weber JM,Turaga KK,et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer[J].Ann Surg Oncol,2010,17(4):1159-1167.DOI:10.1245/s10434-009-0862-1. [14] Scheer RV,Fakiris AJ,Johnstone PAS.Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer[J].Int J Radiat Oncol Biol Phys,2011,80(4):996-1001.DOI:10.1016/j.ijrobp.2010.03.003. [15] Orditura M,Galizia G,Morgillo F,et al. Complete response to preoperative chemoradiation and survival in esophageal cancer:a pooled analysis of three single-institution phase Ⅱ trials[J].Dis Esophagus,2012,25(2):130-136.DOI:10.1111/j.1442-2050.2011.01220.x. [16] Lai SZ,Li WF,Chen L,et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?[J].Int J Radiat Oncol Biol Phys,2011,80(3):661-668.DOI:10.1016/j.ijrobp.2010.03.024. [17] Sher DJ,Koshy M,Liptay MJ,et al. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage Ⅲ non-small cell lung cancer in the National Cancer Data Base[J].Cancer,2014,120(13):2060-2068.DOI:10.1002/cncr.28677. [18] 肖泽芬,章众,张红志,等.用三维治疗计划系统评估食管癌常规放射治疗中肿瘤剂量的分布[J].中华放射肿瘤学杂志,2004,13(4):273-277.DOI:10.3760/j.issn:1004-4221.2004.04.008. Xiao ZF,Zhang Z,Zhang HZ,et al. Assessment of tumor dose distribution in three dimensional conformal radiotherapy treatment planning system for esophageal cancer[J].Chin J Radiat Oncol,2004,13(4):273-277.DOI:10.3760/j.issn:1004-4221.2004.04.008. [19] Lin SH,Wang L,Myles B,et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy for esophageal cancer[J].Int J Radiat Oncol Biol Phys,2012,84(5):1078-1085.DOI:10.1016/j.ijrobp.2012.02.015. [20] Mariette C,Dahan L,Mornex F,et al. Surgery alone versus chemoradiotherapy followed by surgery for stage Ⅰ and Ⅱ esophageal cancer:final analysis of randomized controlled phase Ⅲ trial FFCD 9901[J].J Clin Oncol,2014,32(23):2416-2422.DOI:10.1200/JCO.2013.53.6532.
2016, Vol. 25 
